Huons Co.

Anyang, South Korea

Huons Co.

Anyang, South Korea
SEARCH FILTERS
Time filter
Source Type

News Article | May 18, 2017
Site: marketersmedia.com

— ReportsnReports.com adds new research report on Low Back Pain - Pipeline Review, H1 2017. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse the 37 Tables and 10 Figures, 23 Company Profiles, Spread across 96 Pages Report Available at http://www.reportsnreports.com/reports/992888-low-back-pain-pipeline-review-h1-2017.html . Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants. Low Back Pain - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos SA, Adynxx Inc, AnGes MG Inc, Array BioPharma Inc, Axsome Therapeutics Inc, Boehringer Ingelheim GmbH, Egalet Corp, Frontier Biotechnologies Co Ltd, Gador SA, Grunenthal GmbH, Hisamitsu Pharmaceutical Co Inc, Huons Co Ltd, Immune Pharmaceuticals Inc, KPI Therapeutics Inc, MD Biosciences GmbH, Mesoblast Ltd, Nektar Therapeutics, Orion Oyj, Pacira Pharmaceuticals Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Stayble Therapeutics AB, Sun Pharma Advanced Research Company Ltd Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=992888 . The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 6, 9, 2, 1 and 6 respectively. Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System). • The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System) About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/992888-low-back-pain-pipeline-review-h1-2017.html


The present invention relates to an ophthalmic composition comprising cyclosporine and trehalose as effective components, a method for producing the same, a method for preventing, improving or treating failure caused by ophthalmoxerosis by administering the same, and a use therefor. The ophthalmic composition according to the present invention has a combination of superior effects on ophthalmoxerosis, which can be caused by various factors such as dry air, inflammation, preservatives, etc., and is placed in a variety of states or conditions.


The present invention relates to an ophthalmic composition comprising cyclosporine and trehalose as effective components, a method for producing the same, a method for preventing, improving or treating failure caused by ophthalmoxerosis by administering the same, and a use therefor. The ophthalmic composition according to the present invention has a combination of superior effects on ophthalmoxerosis, which can be caused by various factors such as dry air, inflammation, preservatives, etc., and is placed in a variety of states or conditions.


News Article | May 11, 2017
Site: marketersmedia.com

— Summary Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants. Report Highlights Pharmaceutical and Healthcare latest pipeline guide Low Back Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 6, 9, 2, 1 and 6 respectively. Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Table of Content: Key Points List of Tables List of Figures Introduction Low Back Pain - Overview Low Back Pain - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Low Back Pain - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Low Back Pain - Companies Involved in Therapeutics Development Ache Laboratorios Farmaceuticos SA Adynxx Inc AnGes MG Inc Array BioPharma Inc Axsome Therapeutics Inc Boehringer Ingelheim GmbH Egalet Corp Frontier Biotechnologies Co Ltd Gador SA Grunenthal GmbH Hisamitsu Pharmaceutical Co Inc Huons Co Ltd Immune Pharmaceuticals Inc KPI Therapeutics Inc MD Biosciences GmbH Mesoblast Ltd Nektar Therapeutics Orion Oyj Pacira Pharmaceuticals Inc Pfizer Inc Regeneron Pharmaceuticals Inc Stayble Therapeutics AB Sun Pharma Advanced Research Company Ltd Low Back Pain - Drug Profiles (acetaminophen + caffeine + diclofenac sodium + orphenadrine) - Drug Profile Product Description …Continued For more information, please visit http://www.wiseguyreports.com


Patent
Foundation University and Huons Co. | Date: 2013-01-22

Provided is an ophthalmic composition containing cyclosporine as an active ingredient and including polyethoxylated castor oil or polyethoxylated hydrogenated castor oil, and a method of preparing the same. Particularly, the ophthalmic composition is prepared as a nanoemulsion having a particle diameter of 100 nm or less simply by mixing and stirring an oil phase and an aqueous phase without using a high speed stirring or shearing machine, so that it is very physiochemically stable and storable for a long time. In addition, the ophthalmic composition causes no irritation to eyes.


Kim S.-J.,Sungkyunkwan University | Yoon S.-J.,Sungkyunkwan University | Kim Y.-M.,Huons Co. | Hong S.-W.,Huons Co. | And 3 more authors.
Journal of Ethnopharmacology | Year: 2014

Ethnopharmacological relevance Lonicera japonica Thunberg is a traditional herbal medicine widely used in East Asia as an anti-bacterial, anti-inflammatory, and antiviral agent. This study was designed to investigate the effects of HS-23, ethanol extract of the dried flower buds of Lonicera japonica, in experimental models of sepsis and elucidate the mechanisms of action of HS-23. Materials and methods Male ICR mice were intravenously administered HS-23 (20 and 40 mg/kg) for 0 (immediately) and 24 h after cecal ligation and puncture (CLP) for survival tests, and HS-23 (40 mg/kg) immediately after CLP for biochemical assays. Results HS-23 improved sepsis-induced mortality, enhanced bacterial clearance, and attenuated multiple organ failure. The mechanisms of action of HS-23 included attenuation of increased toll-like receptor (TLR)4 protein and mRNA expression. HS-23 suppressed sepsis-induced increases in protein expression of myeloid differentiation primary response protein 88, p38 and c-Jun N-terminal kinase in both liver and lung, as well as TIR-domain-containing adapter-inducing interferon-β and interferon regulatory transcription factor 3 protein expression in liver. Conclusion The results of this study revealed that HS-23 attenuated sepsis through suppression of TLR signaling pathways. Therefore, our findings suggest that HS-23 might be useful as a potential therapeutic agent for treatment of sepsis. © 2014 Elsevier Ireland Ltd. All rights reserved.


Park S.H.,Chungbuk National University | Roh E.,Chungbuk National University | Kim H.S.,Huons Co. | Baek S.-I.,Chungbuk National University | And 5 more authors.
Biochemical and Biophysical Research Communications | Year: 2013

Lonicerae flos extract (HS-23) is a clinical candidate currently undergoing Phase I trial in lipopolysaccharide (LPS)-injected healthy human volunteers, but its molecular basis remains to be defined. Here, we investigated protective effects of HS-23 or its major constituents on Escherichia coli LPS-induced septic mortality in mice. Intravenous treatment with HS-23 rescued LPS-intoxicated C57BL/6J mice under septic conditions, and decreased the levels of cytokines such as tumor necrosis factor α (TNF-α), interleukin (IL)-1β and high-mobility group box-1 (HMGB-1) in the blood. Chlorogenic acid (CGA) and its isomers were assigned as major constituents of HS-23 in the protection against endotoxemia. As a molecular mechanism, HS-23 or CGA isomers inhibited endotoxin LPS-induced autophosphorylation of the IL-1 receptor-associated kinase 4 (IRAK-4) in mouse peritoneal macrophages as well as the kinase activity of IRAK-4 in cell-free reactions. HS-23 consequently suppressed downstream pathways critical for LPS-induced activation of nuclear factor (NF)-κB or activating protein 1 (AP-1) in the peritoneal macrophages. HS-23 also inhibited various toll-like receptor agonists-induced nitric oxide (NO) production, and down-regulated LPS-induced expression of NF-κB/AP-1-target inflammatory genes in the cells. Taken together, HS-23 or CGA isomers exhibited anti-inflammatory therapy against LPS-induced septic mortality in mice, at least in part, mediated through the inhibition of IRAK-4. © 2013 Elsevier Inc. All rights reserved.


Chae S.-H.,Seoul National University | Kim S.-I.,Nareso Co. | Yeon S.H.,Huons Co. | Perumalsamy H.,Seoul National University | Ahn Y.-J.,Seoul National University
Journal of Economic Entomology | Year: 2014

An assessment was made of the fumigant toxicity of 36 constituents from lemon balm oil (LBO) and summer savory oil (SSO) and another additional nine previously identified compounds of the oils, as well as of the control efficacy of four experimental spray formulations containing individual oils (0.5 and 0.1% sprays) and spinosad 10% suspension concentrate (SC) to females from B- and neonicotinoid-resistant Q-biotypes of Bemisia tabaci (Gennadius) (Homoptera: Aleyrodidae). Based on 24-h LC50 values, Q-biotype females (0.20 μg/cm3) were 40 times less susceptible to dichlorvos than B-biotype females (0.005 μg/cm3). Thymol (LC50, 0.35 μg/cm3) and carvacrol (0.56 μg/cm3) were the most toxic compounds toward Q-biotype females, followed by (1S)-( - )-borneol, α-terpineol, nerol, linalool, and carvone (1.06-1.38 μg/cm 3). The toxicity of these compounds was virtually identical toward both biotype females, indicating that the terpenoids and the insecticides (neonicotinoids and dichlorvos) do not share a common mode of action or elicit cross-resistance. The 0.5% spray of LBO, SSO, and spinosad 10% SC resulted in >90% mortality toward both biotype females. Global efforts to reduce the level of toxic synthetic insecticides in the agricultural environment justify further studies on LBO- and SSO-derived materials as potential contact-action fumigants for the control of B. tabaci populations. © 2014 Entomological Society of America.


Patent
Yonsei University and Huons Co. | Date: 2015-03-11

Provided is an ophthalmic composition containing cyclosporine as an active ingredient and including polyethoxylated castor oil or polyethoxylated hydrogenated castor oil, and a method of preparing the same. Particularly, the ophthalmic composition is prepared as a nanoemulsion having a particle diameter of 100 nm or less simply by mixing and stirring an oil phase and an aqueous phase without using a high speed stirring or shearing machine, so that it is very physiochemically stable and storable for a long time. In addition, the ophthalmic composition causes no irritation to eyes.


The present invention relates to a method for preparing a purified extract of Lonicera Japonica THUNBERG and the composition comprising the same for preventing and treating sepsis and septic shock. The purified extract of purified extract of Lonicera Japonica THUNBERG potent antisepsis activity in severe sepsis CLP model test, the effect on MODS, and the inhibitory effect on various pro-inflammatory cytokines such as TNF-alpha, IL-1beta, IFN-gamma, HMGB-1 etc, as well as it showed unexpectedly synergistic effect on the treatment of sepsis and septic shock in case of combining with the commercially available anti-septic agent such as broad-spectrum anti-biotic to the person skilled in the art, therefore, it can be useful in treating and preventing the sepsis and septic shock as a medicament and health functional food.

Loading Huons Co. collaborators
Loading Huons Co. collaborators